Pfizer announced on Monday, September 22, that it will acquire Metsera, a biotech firm focused on obesity and heart disease treatments, in a deal valued at $4.9 billion.
Under the agreement, Pfizer will purchase all outstanding Metsera shares at $47.50 each, with the transaction expected to close in the fourth quarter of 2025.
CEO Albert Bourla said the acquisition reflects Pfizer’s strategy to invest in high-impact opportunities and secures its entry into the fast-growing obesity drug market. “Obesity is a large and growing space with over 200 health conditions associated with it,” Bourla stated.
The move comes as pharmaceutical companies rush to develop treatments following the success of Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Zepbound.
Pfizer, which saw major profits from its Covid-19 vaccine, has experienced a sharp stock decline since 2021, dropping from $58 per share to $24 as of last Friday. Following the announcement, Pfizer’s stock rose 1.6% in pre-market trading, while Metsera shares jumped 60%.
